Prenosis
Prenosis enables rapid, biology-driven diagnosis and precision therapy in acute care to improve patient outcomes. The company uses its Immunix platform, combining AI and machine learning with biomarker and clinical data to generate real-time immune-response insights and deliver diagnostics and treatment guidance. Its Sepsis ImmunoScore is an FDA-authorized AI diagnostic for sepsis and is deployed through hospital workflows and EMR integrations. Prenosis operates as a B2B SaaS provider to healthcare systems and providers, leveraging a growing clinical biobank to refine models. The platform targets acute care settings where fast decisioning and integration with electronic medical records are critical.
Prenosis
Prenosis enables rapid, biology-driven diagnosis and precision therapy in acute care to improve patient outcomes. The company uses its Immunix platform, combining AI and machine learning with biomarker and clinical data to generate real-time immune-response insights and deliver diagnostics and treatment guidance. Its Sepsis ImmunoScore is an FDA-authorized AI diagnostic for sepsis and is deployed through hospital workflows and EMR integrations. Prenosis operates as a B2B SaaS provider to healthcare systems and providers, leveraging a growing clinical biobank to refine models. The platform targets acute care settings where fast decisioning and integration with electronic medical records are critical.
TL;DR
Headquarters & Focus: Chicago-based AI healthcare company focused on acute care precision medicine
Flagship product: Sepsis ImmunoScore — FDA De Novo–authorized AI diagnostic for sepsis
Platform: Immunix — biomarker + clinical-data platform and biobank for rapid immune-response insights
Business model: B2B SaaS to healthcare systems with EMR integrations
Recent financing: $20M Series A announced Jan 29, 2026 (led by PACE Healthcare Capital) and $20M BARDA contract
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Acute care diagnosis and precision therapy, especially sepsis detection and outcome prediction
Founded
2014
Industry
Biotechnology Research
Tech Stack
Funding Track Record
$20M
Company announced a $20M Series A and a $20M BARDA contract
Listed as most recent Crunchbase funding event in 2023
Investor Signal
“PACE Healthcare Capital led Series A; co-investors include UC Investments, UCI Health Ventures, Labcorp Venture Fund, Global Health Investment Corporation, Illinois DCEO, and Carle Health”